Patent ID: 11946927
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  Y | IPC A  G

Claim 2:
3. The process of claim 1, wherein if the risk value for the selected individual developing IBD is greater than the cut-off value for the prediction logistic regression model used for determining the risk value of an individual developing IBD and if the therapy and any modifications in the therapy for reducing the risk of the selected individual developing IBD does not reduce the risk value for developing IBD below the cut-off value of the prediction logistic regression model used for determining the risk value of an individual developing IBD, the process includes the steps of:
obtaining a blood sample of the individual;
examining the blood sample to obtain a total level of protein in the blood sample and a level of each predictive target biomarker listed in a prediction panel of predictive target biomarkers for determining the risk value of an individual developing UC;
using a prediction logistic regression model that uses the levels of each predictive target biomarker listed in the prediction panel of predictive target biomarkers and the total level of protein in the blood sample to calculate a risk value for the selected individual developing UC;
wherein if the risk value for the selected individual developing UC is above a cut-off value for the prediction logistic regression model for use in determining the risk value of an individual developing UC, administering a therapy to the selected individual for treating UC;
wherein the therapy includes administering a medication for treating UC and repeating the process of determining the risk value for the selected individual developing UC, wherein if the risk value increases or remains the same, making modifications to the therapy for treating UC and repeating the process of determining the risk value for developing UC and continue the therapy or modifying the therapy until the risk value for the selected individual developing UC is below the cut-off value for the prediction logistic regression model for determining the risk value for an individual developing UC;
wherein the prediction panel of predictive target biomarkers for use in determining the risk of an individual developing UC comprises the target biomarkers of HP, SICAM1 and RETN; and
wherein the prediction logistic regression model for determining the risk value for an individual developing UC is Log (p/1−p)=221.7+2.2×RETN+15.1×sICAM1+61.5×HP+4.9×(sICAM1×HP) and wherein the cut-off value is 0.52.